The effect of intra-vitreal injection of bevacizumab for vascular endothelial factor-related intraocular diseases.
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- 24 May 2019 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 24 May 2019 Status changed from not yet recruiting to discontinued.
- 20 May 2014 New trial record